Warner Biddle: Building a commercial model for CAR-T in autoimmune care

About this episode

Warner Biddle discusses the commercial model for CAR-T therapies in autoimmune care.

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Warner Biddle, CEO of Kyverna Therapeutics, to explore how autologous CAR-T therapies can be delivered safely, efficiently, and at scale in autoimmune disease. Warner shares Kyverna’s approach to designing a commercially viable treatment model — one that prioritizes outpatient care, streamlined manufacturing, and real-world practicality. They discuss what it means to bring complex therapies into community settings, how Kyverna is tailoring its rollout strategy by indication, and why the future of CAR-T in autoimmune disease depends as much on delivery as it does on data. Connect with Warner: https://www.linkedin.com/in/warnerbiddle/

People in this episode

Host: Jason C. Foster

Guest: Warner Biddle

Topics covered

• CAR-T therapies
• autoimmune disease
• commercial model
• outpatient care
• manufacturing
• treatment strategy

Keywords

• CAR-T
• autoimmune care
• Kyverna Therapeutics
• treatment model
• outpatient care
• manufacturing
• delivery

Mentioned in this episode

Organizations: Kyverna Therapeutics

More episodes of Ori Spotlight

• Ken Harris: Why AI and automation are CGT’s next inflection point · January 27, 2026 · 1h 3m
• Joe DePinto: Why advanced therapies need a new delivery model · January 13, 2026 · 1h 5m
• Jonathan Gluck: A personal account of navigating myeloma and CAR-T therapy · December 16, 2025 · 56 min
• John Khoury: The CGT developers who adapt new manufacturing techniques early will lead later · December 3, 2025 · 50 min
• Lavakumar Karyampudi: Building early-phase CGT infrastructure for translational success · August 12, 2025 · 1h 0m
• Henrik Andersen: How smart planning helps CGT scale further, faster · July 15, 2025 · 54 min